Table 2.
Reactivity of Determine Combo in plasma specimens from early and established HIV-1 infections from the STOP study.a
| Total | Determine Combo resultsb |
Overall DC positivity | ||||
|---|---|---|---|---|---|---|
| Ag-/Ab- | Ag+/Ab- | Ag+/Ab+ | Ag-/Ab+ | |||
| HIV−1 RNA-positive/ARC-nonreactive/MSc Total (%) | 19 (4.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| HIV-1 RNA-positive/ARC-reactive/MS-negativeTotal (%) | 110 (26.5) | 55 (50.0) | 37 (33.6) | 8 (7.3) | 10 (9.1) | 55 (50.0) |
| HIV-1 RNA-positive/ARC-reactive/MS-indeterminate Total (%) | 14 (3.4) | 3 (21.4) | 1 (7.2) | 3 (21.4) | 7 (50.0) | 11 (78.6) |
| ARC-positive/MS-HIV-1 positive or −undifferentiated Total (%) | 272 (65.5) | 1 (0.4) | 0 (0) | 8 (2.9) | 263 (96.7) | 271 (99.6) |
| Total (%) | 415 (100) | 59 (14.2) | 38 (9.2) | 19 (4.6) | 280 (67.5) | 337 (81.2) |
a
Plasma testing: HIV-1 RNA: GenProbe APTIMA or Abbott m2000 HIV-1 RNA viral load, ARC: Abbott ARCHITECT HIV Ag/Ab (screening assay), MS: Bio-Rad Multispot HIV-1/HIV-2 (supplemental assay).
b
Ag: antigen, Ab: antibody, −: negative, +: positive.
c
MS was not performed.